CVR number 35210458
Industry 46.4610 Wholesale of pharmaceutical goods

DK Venture ApS

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...
Bankruptcy Risk 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Bankruptcy risk for industry  1.1% 1.1% 1.1% 1.1% 1.1%  
Bankruptcy risk  4.1% 6.0% 6.0% 31.1% 33.1%  
Credit score (0-100)  50 39 37 1 0  
Credit rating  BBB BBB BBB C C  
Credit limit (kDKK)  0.0 0.0 0.0 -0.0 -0.0  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Net sales  0 0 0 0 0  
Gross profit  1,966 5,962 3,523 281 9.8  
EBITDA  146 4,799 2,403 -283 1,228  
EBIT  146 4,799 2,403 -7,439 618  
Pre-tax profit (PTP)  143.4 4,725.1 2,053.8 -8,099.6 540.5  
Net earnings  109.7 3,682.4 1,592.5 -8,099.6 540.5  
Pre-tax profit without non-rec. items  143 4,725 2,054 -8,100 541  
 
See the entire income statement

Balance sheet (kDKK) 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  1,111 3,039 4,631 -3,468 -2,928  
Interest-bearing liabilities  0.2 2,000 0.1 51.4 1.2  
Balance sheet total (assets)  2,767 13,839 15,180 3,482 376  
Net Debt  -1,224 -1,730 -4,294 51.4 1.1  
 
See the entire balance sheet

Volume 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  1,966 5,962 3,523 281 9.8  
Gross profit growth  12.2% 203.2% -40.9% -92.0% -96.5%  
Employees  4 4 4 2 1  
Employee growth %  33.3% 0.0% 0.0% -46.5% -53.3%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  2,767 13,839 15,180 3,482 376  
Balance sheet change%  28.2% 400.1% 9.7% -77.1% -89.2%  
Added value  145.8 4,799.4 2,403.4 -7,438.6 1,228.0  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  -12 0 0 -7,156 -610  
Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  3.0 4.0 5.0 -1.0 1.0  

Profitability 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  7.4% 80.5% 68.2% -2,650.6% 6,282.0%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  5.9% 58.0% 16.6% -67.5% 12.2%  
ROI %  13.1% 156.6% 47.7% -292.1% 2,380.2%  
ROE %  9.9% 177.5% 41.5% -199.7% 28.0%  

Solidity 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Equity ratio %  40.1% 22.0% 30.5% -49.9% -88.6%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  -839.5% -36.1% -178.7% -18.2% 0.1%  
Gearing %  0.0% 65.8% 0.0% -1.5% -0.0%  
Net interest  0 0 0 0 0  
Financing costs %  29.5% 8.9% 35.9% 2,378.7% 324.9%  

Liquidity 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Quick Ratio  1.0 1.2 1.3 0.5 0.1  
Current Ratio  1.6 1.3 1.5 0.5 0.1  
Cash and cash equivalent  1,224.5 3,730.3 4,294.0 0.0 0.1  

Capital use efficiency 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  957.2 2,998.8 5,024.9 -3,527.2 -2,927.6  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Net sales / employee  0 0 0 0 0  
Added value / employee  36 1,200 601 -3,477 1,228  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  36 1,200 601 -132 1,228  
EBIT / employee  36 1,200 601 -3,477 618  
Net earnings / employee  27 921 398 -3,786 541